In This Section

Behavioral Pharmacology of Biased Agonists

Thursday April 29, 2021

1:30 pm - 3:00 pm Eastern Time (ET)

View session on the EB Virtual Platform (EB registration required)

BEH DDD MP NEU

Chair :

William Fantegrossi
University of Arkansas for Medical Sciences



Development of “biased ligands” preferentially activating specific signaling pathways by stabilizing subsets of receptor conformations that invoke distinct G protein-dependent or -independent signaling are underway. Development of novel analgesics acting via CB1, μ-, δ- and κ-opioid receptors is focused on identification of G protein-selective compounds that are devoid of β-arrestin 2 recruitment because evidence suggests that this may reduce adverse effects. Results of these efforts appear promising in vitro, but in vivo confirmation of biased agonism is relatively rare. This symposium will survey biased agonism across pharmacological classes, focusing on behavioral effects which may differentiate them from traditional unbiased agonists.

Speakers

Mei-Chuan (Holden) Ko - Wake Forest University

In vivo Evaluation of G Protein Biased Agonists at Mu-opioid Receptors in Non-human Primates

Provide a brief description of your talk appropriate for publication. Limit your talk description to 2-3 sentences.

Paul Prather - University of Arkansas for Medical Sciences

Characterization of Structurally Novel G Protein Biased CB1 Agonists

Provide a brief description of your talk appropriate for publication. Limit your talk description to 2-3 sentences.

Charles Nichols - LSU New Orleans

Functional Selectivity at the Serotonin 5-HT2A Receptor

Provide a brief description of your talk appropriate for publication. Limit your talk description to 2-3 sentences.

Mehrdad Shamloo - Stanford University School of Medicine

Biased Agonism at Beta-1 Adrenergic Receptors as a Novel Treatment Strategy for Alzheimer's Disease

Provide a brief description of your talk appropriate for publication. Limit your talk description to 2-3 sentences.